Skip to main content

Advertisement

SpringerLink
Log in

Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Background

Angiogenesis is important in tumor growth and metastasis. Germ-line polymorphisms critical to the angiogenesis pathway have been shown to confer prognostic information in multiple tumor types. These genes include vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS).

Experimental design

We extracted DNA from 53 specimens obtained from 21 patients including a primary breast tumor, and/or a histologically involved lymph node, and/or a histologically normal lymph node. We subsequently genotyped all specimens to evaluate two polymorphisms in the eNOS gene and one polymorphism in the VEGF gene.

Results

Chromatographs were generated in 145/159 (91%) samples. When assessing all polymorphisms by site, chromatographs were generated in 42/51 (83%) samples obtained from the primary tumor and 103/108 (95%) from lymph nodes. Chromatographs were generated in 46/53 (87%) samples from the T−786C polymorphism in the 5′-flanking region in the eNOS gene, 49/53 (92%) when assessing the Glu298Asp polymorphism in exon 7 in the eNOS gene and 50/53 samples (94%) for the C936T polymorphism in the VEGF gene. There was 100% concordance between analyses from the primary tumor, uninvolved lymph node, and involved lymph node from the same case.

Conclusion

We successfully extracted DNA and genotyped several polymorphisms in two genes important in angiogenesis. These genotypes were determined in breast tumors, but also in involved and uninvolved lymph nodes. There was concordance between the genotypes of germline DNA obtained from uninvolved lymph nodes and those determined in tumor samples, implying that the host angiogenic genotype imprints the tumor genotype.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Folkman J, Angiogenesis-dependent diseases Semin Oncol 2001, 28(6):536–542

    Article  CAS  PubMed  Google Scholar 

  2. Folkman J, Tumor angiogenesis Adv Cancer Res 1985, 43: 175–203

    Article  CAS  PubMed  Google Scholar 

  3. Folkman J, Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1995, 1(1):27–31

    Article  CAS  PubMed  Google Scholar 

  4. Plate KH, Breier G, Risau W, Molecular mechanisms of developmental and tumor angiogenesis Brain Pathol 1994, 4(3):207–218

    Article  CAS  PubMed  Google Scholar 

  5. Weinstat-Saslow D, Steeg PS, Angiogenesis and colonization in the tumor metastatic process: basic and applied advances Faseb J1994, 8(6):401–407

    CAS  PubMed  Google Scholar 

  6. Parangi S, O’Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, Hanahan D, Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA1996, 93(5):2002–2007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Schneider BP, Miller KD, Angiogenesis of breast cancer J Clin Oncol 2005, 23(8):1782–1790

    Article  CAS  PubMed  Google Scholar 

  8. Miller K, Sledge GW: Dimming the blood tide: Angiogenesis, antiangiogenic therapy and breast cancer. In: Nabholtz JM (ed) Breast Cancer Management Application of Clinical and Translational Evidence to Patient Care (2nd edn). Lippincott Williams & Wilkins, Philadelphia, 2003: 287–308

  9. Guinebretiere JM, Le Monique G, Gavoille A, Bahi J, Contesso G, Angiogenesis and risk of breast cancer in women with fibrocystic disease J Natl Cancer Inst 1994, 86(8):635–636

    Article  CAS  PubMed  Google Scholar 

  10. Guidi AJ, Fischer L, Harris JR, Schnitt SJ, Microvessel density and distribution in ductal carcinoma in situ of the breast J Natl Cancer Inst 1994, 86(8):614–619

    Article  CAS  PubMed  Google Scholar 

  11. Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF, Brown LF, Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast Cancer 1997, 80(10):1945–1953

    Article  CAS  PubMed  Google Scholar 

  12. Weidner N, Semple JP, Welch WR, Folkman J, Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma N Engl J Med 1991, 324(1):1–8

    Article  CAS  PubMed  Google Scholar 

  13. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G, Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma J Natl Cancer Inst 1992, 84(24):1875–1887

    Article  CAS  PubMed  Google Scholar 

  14. Ragaz JMK, Badve S, et al.: Adverse association of expressed vascular endothelial growth factor (VEGF), Her2, Cox2, uPA and EMSY with long-term outcome of stage I–III breast cancer (BrCa). Results from the British Columbia Tissue Microarray Project. In: Proc Am Soc Clin Oncol. 2004

  15. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P et al, Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma J Natl Cancer Inst 1997, 89(2):139–147

    Article  CAS  PubMed  Google Scholar 

  16. Gasparini G, Toi M, Miceli R, Vermeulen PB, Dittadi R, Biganzoli E, Morabito A, Fanelli M, Gatti C, Suzuki H et al, Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy Cancer J Sci Am 1999, 5(2):101–111

    CAS  PubMed  Google Scholar 

  17. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, van der Kwast TH, Sweep CG, Klijn JG, High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res 2001, 61(14):5407–5414

    CAS  PubMed  Google Scholar 

  18. Lin CC, Wu HC, Tsai FJ, Chen HY, Chen WC, Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for prostate cancer Urology 2003, 62(2):374–377

    Article  PubMed  Google Scholar 

  19. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM, Influence of cytokine gene polymorphisms on the development of prostate cancer Cancer Res 2002, 62(12):3369–3372

    CAS  PubMed  Google Scholar 

  20. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H, A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk Int J Cancer 2003, 106(4):468–471

    Article  CAS  PubMed  Google Scholar 

  21. Cheon KT, Choi KH, Lee HB, Park SK, Rhee YK, Lee YC, Gene polymorphisms of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer Lung 2000, 178(6):351–360

    Article  CAS  PubMed  Google Scholar 

  22. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C, Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer Eur J Cancer Prev 2002, 11(4):343–350

    Article  CAS  PubMed  Google Scholar 

  23. Iughetti P, Suzuki O, Godoi PH, Alves VA, Sertie AL, Zorick T, Soares F, Camargo A, Moreira ES, di Loreto C et al, A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma Cancer Res 2001, 61(20):7375–7378

    CAS  PubMed  Google Scholar 

  24. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM, Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma Genes Immun 2002, 3(4):229–232

    Article  CAS  PubMed  Google Scholar 

  25. Balasubramanian SP, Brown NJ, Reed MW, Role of genetic polymorphisms in tumour angiogenesis Br J Cancer 2002, 87(10):1057–1065

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Ghilardi G, Biondi ML, Cecchini F, DeMonti M, Guagnellini E, Scorza R, Vascular invasion in human breast cancer is correlated to T–>786C polymorphism of NOS3 gene Nitric Oxide 2003, 9(2):118–122

    Article  CAS  PubMed  Google Scholar 

  27. Hefler LA, Ludwig E, Lampe D, Zeillinger R, Leodolter S, Gitsch G, Koelbl H, Tempfer CB, Polymorphisms of the endothelial nitric oxide synthase gene in ovarian cancer Gynecol Oncol 2002, 86(2):134–137

    Article  CAS  PubMed  Google Scholar 

  28. Medeiros RM, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Ferreira P, Lopes C, Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu–Asp298 polymorphism at exon 7 Clin Cancer Res 2002, 8(11):3433–3437

    CAS  PubMed  Google Scholar 

  29. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K et al, Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance Carcinogenesis 2003, 24(11):1779–1783

    Article  CAS  PubMed  Google Scholar 

  30. Langsenlehner U, Samonigg H, Krippl P, Vascular Endothelial Growth Factor gene polymorphism decreases the risk for breast cancer metastasis Breast Cancer Res Treat 2004, 88:S72

    Google Scholar 

  31. Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD, Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples Pharmacogenetics 2003, 13(8):501–507

    Article  CAS  PubMed  Google Scholar 

  32. Tanus-Santos JE, Desai M, Flockhart DA, Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants Pharmacogenetics 2001, 11(8):719–725

    Article  CAS  PubMed  Google Scholar 

  33. Tanus-Santos JE, Desai M, Deak LR, Pezzullo JC, Abernethy DR, Flockhart DA, Freedman JE, Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol Pharmacogenetics 2002, 12(5):407–413

    Article  CAS  PubMed  Google Scholar 

  34. Fienberg SE: The Analysis of Cross Classified Categorical Data (2nd edn). Cambridge, Mass, 1983

  35. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 2004, 350(21):2129–2139

    Article  CAS  PubMed  Google Scholar 

  36. Harvey JM, Clark GM, Osborne CK, Allred DC, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 1999, 17(5):1474–1481

    Article  CAS  PubMed  Google Scholar 

  37. Yamauchi H, Stearns V, Hayes DF, When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer J Clin Oncol 2001, 19(8):2334–2356

    Article  CAS  PubMed  Google Scholar 

  38. Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski CC, Hausmaninger H, Kubista E, Samonigg H et al, High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin J Clin Oncol 2003, 21(19):3594–3600

    Article  CAS  PubMed  Google Scholar 

  39. Harbeck N, Kates RE, Schmitt M, Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination J Clin Oncol 2002, 20(4):1000–1007

    Article  PubMed  Google Scholar 

  40. Broet P, Romain S, Daver A, Ricolleau G, Quillien V, Rallet A, Asselain B, Martin PM, Spyratos F, Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 2001, 19 (11):2778–2787

    Article  CAS  PubMed  Google Scholar 

  41. Lenz HJ, The use and development of germline polymorphisms in clinical oncology J Clin Oncol 2004, 22(13):2519–2521

    Article  CAS  PubMed  Google Scholar 

  42. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson IV, Harden PN, Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection J Am Soc Nephrol 2002, 13(1):260–264

    CAS  PubMed  Google Scholar 

  43. Evans WE, McLeod HL, Pharmacogenomics–drug disposition, drug targets, and side effects N Engl J Med 2003, 348(6):538–549

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Supported in part by the Breast Cancer Research Foundation and Walther Medical Foundation (GWS). Drs. Flockhart and Skaar are supported by the NIGMS Pharmacogenetics Research Network through U-01GM61373 (D.F.), and a clinical pharmacology training grant 5T32-GM-08425 (D.F) from the National Institute of General Medical Sciences, Bethesda, MD.

Author information

Authors and Affiliations

  1. Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA

    Bryan P. Schneider, Todd C. Skaar & David A. Flockhart

  2. Division of Hematology–Oncology, Indiana University School of Medicine, Indianapolis, IN, USA

    Bryan P. Schneider & George W. Sledge

  3. Departments of Medicine and Pathology, Indiana University School of Medicine, Indianapolis, IN, USA

    Sunil Badve

  4. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN, USA

    Lang Li

Authors
  1. Bryan P. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Todd C. Skaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. George W. Sledge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sunil Badve
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. David A. Flockhart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bryan P. Schneider.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schneider, B.P., Skaar, T.C., Sledge, G.W. et al. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res Treat 96, 209–215 (2006). https://doi.org/10.1007/s10549-005-9003-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-005-9003-0

Key words

Search

Navigation